Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.
The term sheet is binding on the parties and is to be superseded by a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026; if a definitive agreement is not signed by that date,
Psyence's medical unit signed a deal to sell a special medicine in the US. This shows the company is moving forward with its business plan and real products.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.